NHD Global
Metabolic & Weight Loss · Triple-receptor research
Scientific Product Dossier
Retatrutide is an investigational peptide agonist designed to activate GIP, GLP-1 and glucagon receptors. Published Phase 2 research reports body-weight and metabolic outcomes in a controlled human study. FDA states that retatrutide is not a component of an approved drug and has not been found safe and effective for any condition. This catalog material is for research use only.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
The Phase 2 obesity trial reported mean weight reductions up to 24.2% at 48 weeks in the highest studied group, compared with 2.1% for placebo.
Investigational human trial result with protocol-specific groups and monitoring; not proof of efficacy or safety for catalog material.
Read the primary studyFDA states that retatrutide is not a component of an FDA-approved drug and has not been found safe and effective for any condition.
FDA also warns that “research purposes” wording does not convert an unapproved product into an approved medicine.
Read the primary studyLilly reported mean weight changes of −28.3% at 80 weeks for the TRIUMPH-1 12 mg group, up to −20.8% in TRIUMPH-2 and −22.6% in TRIUMPH-3.
Primary-sponsor topline disclosures. ClinicalTrials.gov still showed No Results Posted for TRIUMPH-1; full peer-reviewed methods and complete safety tables remain pending.
Read the primary studyThe peer-reviewed Phase 2 trial reported gastrointestinal adverse events as the most common events and a dose-dependent increase in heart rate.
Investigational clinical-trial evidence; not a safety determination for catalog material.
Read the primary studyAmong 338 adults, mean weight change at week 48 was −24.2% in the 12 mg study group versus −2.1% with placebo. The primary endpoint was week 24, when these values were −17.5% and −1.6%.
These are trial-group results, not dosing instructions. Gastrointestinal events were common and dose-related; heart-rate increases were also reported. This is a selected 2023 study, not a summary of every subsequent trial.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 15 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 20 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 30 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 40 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 50 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 60 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 100 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
Randomized, double-blind, placebo-controlled, dose-ranging clinical research over 48 weeks.
View primary recordPrimary registry record for the Phase 2 obesity study, including design, enrollment and outcome framework.
View primary recordThird-party publications selected for direct relevance.
Jastreboff AM, et al. N Engl J Med. 2023;389:514–526. PMID 37366315.
ClinicalTrials.gov record NCT04881760.
U.S. Food and Drug Administration. Content current through May 31, 2026.
Eli Lilly and Company. May 21, 2026. Sponsor news release; not a full peer-reviewed report.
Eli Lilly and Company. July 23, 2026. Sponsor news release; detailed publication pending.
Concise answers for researchers comparing identity, evidence and catalog variants.
Retatrutide is an investigational peptide designed to activate GIP, GLP-1 and glucagon receptors.
No. It remains an investigational compound in clinical development.
The 48-week trial reported dose-dependent body-weight reductions, with the highest studied group reaching a mean 24.2% reduction. This does not validate catalog research material or provide dosing guidance.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
A close reading of retatrutide’s GIP, GLP-1 and glucagon receptor pharmacology and the 48-week phase 2 obesity trial, including limitations and current investigational status.
Updated August 28, 2026
A 2026 evidence map separating published retatrutide phase 2 data, completed phase 3 study records, unposted results and regulatory status.
Updated August 28, 2026Source-traceable evidence
Structured readings of published studies, with the model, result and translation boundary stated explicitly.
A source-traceable reading of the randomized Phase 2 obesity trial, including the dose-group results, adverse-event pattern and the limits of applying a clinical intervention record to…
Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Published-study results are tied to the linked records and kept separate from catalog-lot claims. Imported purity, storage and document-availability templates have been removed pending product- and lot-specific confirmation.
Technical procurement
Selected: RT30 · 30 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
